Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110387359B discloses engineered enzymes for efficient statin production, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN111944855B details a high-yield enzymatic route for (R)-1-(4-(benzyloxy)-3-nitrophenyl)-2-bromoethanol, offering superior stereoselectivity.
Patent CN113249417B reveals a biocatalytic route for chiral cis-beta-aryl-beta-hydroxy-alpha-amino esters using KRED-Bt, offering high stereoselectivity and industrial scalability.
Patent CN118126972A reveals enhanced enzyme mutant for (S)-NBHP production offering superior acid resistance and reduced processing costs for pharmaceutical supply chains.
Patent CN103255183B details enzymatic asymmetric reduction for high-purity intermediates. Offers significant cost reduction and supply chain reliability for statin synthesis.
Patent CN106164260B enables high-yield biocatalytic synthesis of (R)-6-hydroxy-8-chlorooctanoate. Discover cost-effective supply chain solutions for lipoic acid precursors.
Patent CN115433721B details a carbonyl reductase mutant for BHBM synthesis, offering water-based media and superior thermal stability for cost-effective pharma manufacturing.
Novel carbonyl reductase mutants enhance chiral alcohol synthesis yield and stability for pharmaceutical manufacturing supply chains ensuring reliable high-purity intermediate sourcing.
Patent CN109182410B details a high-yield biocatalytic route for chiral piperidine intermediates, offering significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN113174377A reveals stable carbonyl reductase mutants for high-yield diltiazem intermediate synthesis, offering cost-effective biocatalysis solutions.
Patent CN106701698A reveals high-efficiency enzymatic synthesis for chiral alcohols. Offers cost reduction and high purity for pharmaceutical supply chains.
Patent CN104789505B reveals enzymatic route for high purity statin intermediates. Offers cost reduction and supply reliability for pharmaceutical manufacturing.
Patent CN114410599A demonstrates enhanced enzymatic efficiency for rosuvastatin side chains offering substantial cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Novel carbonyl reductase mutants enable high-yield rosuvastatin intermediate production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN103497911B reveals ChKRED20 enzyme for high-efficiency synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing globally.
Patent CN104630125B reveals engineered E. coli for high-purity statin intermediate synthesis with mild conditions and reduced processing complexity.
Patent CN109837317B details a novel enzymatic method for synthesizing high-purity chiral alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN108486075A details a mutant enzyme for statin side chains, offering enhanced catalytic efficiency and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN111235123A reveals a novel carbonyl reductase enabling high-substrate loading biocatalysis, offering significant cost reduction and purity advantages for pharmaceutical manufacturing.
Patent CN112708641A discloses a high-efficiency chemo-enzymatic route for tomoxetine. Achieves >99.9% ee and high substrate loading for cost-effective manufacturing.